Orexigen, Arena Shares Benefit
FDA Review Spurs Confidence in Qnexa Despite Safety Issues
WASHINGTON – While the FDA determined that Vivus Inc.'s obesity pill Qnexa (phentermine/topiramate) met the agency's 2007 criteria for efficacy in weight loss, regulators said teratogenicity, along with metabolic acidosis and adverse psychiatric, cognitive and cardiovascular events were concerns of "particular interest" with the drug. (BioWorld Today)